ICYMI: FDA Clears First DNA Immunotherapy for Rare Airway Disease
3 Articles
3 Articles
A treatment that injects DNA to induce human cells to produce viral proteins, prompting the immune system to attack them, has been approved for the first time in the United States. This marks the commercialization of technology, previously primarily used in vaccine development, into a pharmaceutical product to treat actual diseases. ◇ Injecting DNA containing viral information… Awakening the body's immune response. On the 30th of last month (loc…
Silver Spring – The US FDA has approved plasmid-based DNA immunotherapy for the treatment of recurrent respiratory papillomatosis. Based on the results of a Phase 1/2 study, Voceryq (Doruxapapogene Ralaplasmide plus Lalikinogene Sifuplasmide-gxfd) in adults was the rate of the surgical treatment of...
ICYMI: FDA Clears First DNA Immunotherapy for Rare Airway Disease
WASHINGTON, D.C. — In case you missed it, the U.S. Food and Drug Administration granted accelerated approval last week to Inovio Pharmaceuticals’ Voceryq, the first plasmid DNA-based immunotherapy authorized in the United States, offering adults with recurrent respiratory papillomatosis a treatment that could reduce the need for repeated airway surgeries. The approval introduces a nonsurgical treatment option for recurrent respiratory papillomat…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
